MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

BACKGROUND: Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Belvís, Robert, Irimia, Pablo, Pozo-Rosich, Patricia, González-Oria, Carmen, Cano, Antonio, Viguera, Javier, Sánchez, Belén, Molina, Francisco, Beltrán, Isabel, Oterino, Agustín, Cuadrado, Elisa, Gómez-Camello, Angel, Alberte-Woodward, Miguel, Jurado, Carmen, Oms, Teresa, Ezpeleta, David, de Terán, Javier Díaz, Morollón, Noemí, Latorre, Germán, Torres-Ferrús, Marta, Alpuente, Alicia, Lamas, Raquel, Toledano, Carlos, Leira, Rogelio, Santos, Sonia, del Río, Margarita Sánchez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285868/
https://www.ncbi.nlm.nih.gov/pubmed/34273947
http://dx.doi.org/10.1186/s10194-021-01267-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285868/
https://www.ncbi.nlm.nih.gov/pubmed/34273947
http://dx.doi.org/10.1186/s10194-021-01267-x

Ejemplares similares